Flexible Endoscopes Market: as Olympus FY2025 Endoscopic Solutions Division revenue of JPY 997.33 Billion at 6.53% growth led by North America EVIS X1 double-digit adoption and 44% GI system sales growth in Q2 FY2025 establishes the commercial scale of the global flexible endoscopy infrastructure, Ambu A/S FY2024/25 Endoscopy division growing 15.4% organic on aScope volume confirms that single-use flexible endoscopes are capturing procedure categories from reusable scopes, so Olympus EZ1500 EDOF FDA 510(k) clearance in May 2025 and Ambu aScope 5 Cysto HD FDA clearance in June 2025 define the next-generation imaging and single-use capability frontier shaping hospital endoscopy equipment capital decisions through the forecast period.

The global flexible endoscopes market size was USD 2.38 Billion in 2025 and is expected to register a revenue CAGR of 5.1% during the forecast period. Market revenue growth is driven by factors such as Olympus FY2025 ESD revenue of JPY 997.33 Billion at 6.53% growth confirming sustained GI endoscopy procedure volume expansion globally, Ambu A/S FY2024/25 Endoscopy organic growth of 15.4% establishing single-use flexible endoscopes as a structurally growing market segment capturing infection-sensitive procedure categories from reusable scopes, and as well as next-generation imaging platform launches including the Olympus EZ1500 EDOF FDA clearance in May 2025 and the Ambu aScope 5 Cysto HD clearance in June 2025 creating capital equipment upgrade cycles at hospital endoscopy departments evaluating enhanced image quality for complex therapeutic procedures. The first driving factor is Olympus Endoscopic Solutions Division FY2025 revenue of JPY 997.33 Billion at 6.53% growth, with Q2 FY2025 North America GI system sales growing 44% and FY2024 ESD revenue of approximately JPY 586 Billion, confirming sustained GI endoscopy procedure volume expansion at North American hospital endoscopy departments where EVIS X1 system adoption is driving reusable flexible scope capital replacement at premium price points above prior-generation EVIS platform scopes. The second driving factor is Ambu A/S Endoscopy Division FY2024/25 revenue of DKK 6,037 Million at 15.4% organic growth on aScope bronchoscope, cystoscope, and ERCP scope volumes, confirming that single-use flexible endoscopes are achieving the commercial adoption scale that captures infection-sensitive procedure categories from reusable endoscope workflows at hospital infection control departments implementing single-use scope policies for CRE outbreak prevention and staff safety. The third driving factor is next-generation imaging platform innovation creating capital equipment upgrade cycles, with Olympus EZ1500 EDOF receiving FDA 510(k) clearance in May 2025 for enhanced depth-of-field imaging in upper GI endoscopy and Ambu aScope 5 Cysto HD receiving FDA clearance in June 2025 as the first single-use high-definition cystoscope for percutaneous nephrolithotomy, both creating new capital procurement decision cycles at hospital endoscopy departments evaluating next-generation platform capabilities. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way the Olympus EVIS X1 platform's installed base penetration at North American hospital endoscopy departments creates a compounding capital replacement cycle for the broader flexible scope inventory at each account, which allows the EVIS X1 system adoption cycle to generate multiple per-account capital transactions as gastroscope, colonoscope, duodenoscope, and specialty scope categories are sequentially upgraded to EVIS X1 compatibility at each converting endoscopy department. Once a hospital endoscopy department commits to the EVIS X1 platform through the initial gastroscope procurement, the compatibility requirement for EVIS X1 accessories, light sources, and processors creates an institutional incentive to upgrade the remaining scope inventory to EVIS X1-compatible models to enable the integrated imaging capabilities across the full procedure menu, so the capital replacement cycle per account extends beyond the initial scope procurement into a multi-year scope inventory refresh. As a result, demand and revenue share are concentrating around the platforms with the most comprehensive EVIS X1-compatible scope portfolio breadth and the deepest hospital endoscopy department service relationships, and the forecast tilts toward these installed-base replacement cycle platforms rather than single-scope competitive entries without equivalent platform breadth. For instance, in January 2024, Olympus completed the Taewoong Medical and Canon Medical EUS collaboration, one of several transactions that shaped the flexible endoscope competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the sustained growth of the global GI endoscopy procedure volume that generates per-account capital replacement and consumable accessory demand across the Olympus flexible endoscope installed base, demonstrated by Olympus ESD FY2025 revenue of JPY 997.33 Billion at 6.53% growth and the exceptional Q2 FY2025 performance with North America GI system sales growing 44%. EVIS X1 adoption works commercially because the EVIS X1 platform delivers 1.4 times higher spatial resolution and 4 times wider field of view compared to prior-generation EVIS systems, creating meaningful diagnostic image quality differentiation that drives hospital endoscopy department capital committees to commit to premium-priced EVIS X1 scope procurement at accounts that had deferred reusable scope capital replacement during the post-pandemic capital budget constraint period. Olympus FY2024 Endoscopic Solutions Division revenue of approximately JPY 586 Billion established the base from which FY2025 JPY 997.33 Billion at 6.53% growth reflects both organic volume growth and EVIS X1 platform adoption across the North American, European, and Asia Pacific hospital endoscopy department installed base. The Olympus EZ1500 EDOF received FDA 510(k) clearance in May 2025, adding enhanced depth-of-field imaging to the upper GI endoscopy platform for improved complex lesion characterisation at academic endoscopy centres. Olympus also completed the Taewoong Medical and Canon Medical EUS collaboration in January 2024, expanding the EVIS X1 ecosystem accessories portfolio. These are some of the key factors driving revenue growth of the market.

The second driver is the structural transition of infection-sensitive flexible endoscopy procedure categories from reusable to single-use scope formats, driven by Ambu A/S's commercial scale and FDA clearance execution demonstrating that single-use flexible endoscopes have achieved the image quality, procedure coverage, and commercial availability needed to capture meaningful procedure share from reusable scopes at hospital accounts prioritising infection control outcomes over per-procedure scope cost. Single-use scope adoption works commercially because each hospital department that converts a high-risk procedure category including ERCP, flexible bronchoscopy in intubated ICU patients, and urological flexible cystoscopy to single-use scopes eliminates the scope reprocessing liability associated with reusable scope contamination between patients, which hospital risk management teams increasingly value above the per-procedure cost premium of single-use formats. Ambu A/S reported FY2024/25 Endoscopy Division revenue of DKK 6,037 Million at 15.4% organic growth, confirming that single-use bronchoscope, cystoscope, and ERCP aScope volumes are sustaining above-market growth as more hospital accounts transition infection-sensitive procedure categories to single-use formats. In June 2025, Ambu received FDA clearance for the aScope 5 Cysto HD, the first single-use high-definition cystoscope for PCNL, expanding Ambu's single-use scope portfolio into a urology application that previously required reusable reprocessed cystoscopes. These are some of the key factors driving revenue growth of the market.

Olympus FY2025 Endoscopic Solutions Division revenue reached JPY 997.33 Billion at 6.53% growth, with North America Q2 FY2025 GI system sales growing 44%. At approximately 70% market share in flexible GI endoscopes globally, Olympus's FY2025 performance confirms that EVIS X1 platform adoption at North American hospital endoscopy departments is generating an above-market capital replacement cycle that sustains premium per-scope ASPs well above prior-generation EVIS system pricing, creating a durable revenue growth layer above underlying GI procedure volume expansion.

The third driver is the product innovation cadence creating capital upgrade evaluation cycles at hospital endoscopy departments that accelerate replacement decisions beyond the standard 5 to 7 year scope depreciation schedule, because meaningful imaging capability improvements generate clinical champion pressure at hospital endoscopy department directors to upgrade sooner than the depreciation schedule would otherwise trigger. Innovation-driven capital cycles work commercially because the Olympus EZ1500 EDOF's enhanced depth-of-field imaging capability for complex upper GI lesion characterisation and Barrett's surveillance provides the academic endoscopy centre gastroenterology chief with a clinical differentiation argument that justifies early scope replacement before the existing fleet reaches end of useful life, generating capital procurement revenue above the baseline replacement cycle that sustains platform growth. Olympus received FDA 510(k) clearance for EZ1500 EDOF in May 2025, creating a technology migration trigger at academic endoscopy centres performing complex upper GI therapeutic procedures. Ambu received FDA clearance for aScope 5 Cysto HD in June 2025 as the first single-use high-definition cystoscope for percutaneous nephrolithotomy, creating a new clinical procedure category for single-use flexible urological endoscopy that did not have an established reusable scope equivalent validated for PCNL. Karl Storz completed the Surgical Inc. acquisition in August 2024 and ANKLIN acquisition in January 2025, expanding its flexible endoscopy accessory and service portfolio in North American and European hospital markets. These are some of the key factors driving revenue growth of the market.

However, the flexible endoscopes market faces adoption constraints from single-use scope disruption reducing reusable scope volume in high-risk procedure categories and from China hospital procurement pricing pressure on Asia Pacific flexible scope revenue. Because Ambu 15.4% organic Endoscopy growth and the June 2025 aScope 5 Cysto HD clearance demonstrate that single-use flexible endoscope adoption is expanding from bronchoscopy into urological and ERCP procedure categories, each converting hospital department permanently reduces the reusable flexible scope replacement volume in that clinical application at converting accounts, creating a structural revenue headwind for reusable GI endoscope and bronchoscope replacement cycles as single-use scope adoption in the highest-infection-risk procedure applications progresses through the 2026 to 2030 period. China hospital procurement centralisation and price negotiation rounds for hospital endoscopy equipment have maintained average selling price pressure on flexible endoscope capital at Chinese hospital accounts, constraining Olympus Asia Pacific flexible scope revenue growth below the underlying GI procedure volume expansion rate and limiting the margin contribution of Olympus China volume growth to the company's overall ESD financial performance. Reprocessing cost and regulatory compliance burden for reusable duodenoscopes and ERCP scopes are the third constraint, as FDA guidance on duodenoscope reprocessing creates institutional compliance pressure at US hospital infection control programmes that is accelerating single-use ERCP scope evaluation at accounts that have managed duodenoscope reprocessing under the prior validated HLD protocol framework. These factors substantially limit flexible endoscopes market growth over the forecast period.

Based on product, the global flexible endoscopes market is segmented into GI endoscopes, bronchoscopes and pulmonary endoscopes, urological flexible endoscopes, and ENT and other flexible endoscopes. GI endoscopes hold the largest revenue share at approximately 68%, anchored by Olympus EVIS X1 gastroscope, colonoscope, and duodenoscope platform adoption at North American and European hospital endoscopy departments and FUJIFILM ELUXEO 7000 series GI endoscope placements at academic medical centres. Single-use bronchoscopes are expected to register the most rapid revenue growth rate in the flexible endoscopes market over the forecast period, driven by Ambu aScope 5 Bronchoscope and Olympus single-use bronchoscope adoption at hospital ICU and pulmonology departments implementing single-use bronchoscopy protocols for ventilated patient populations.

Based on end-use, the global flexible endoscopes market is segmented into hospitals and endoscopy centres, ambulatory surgical centres, and specialty clinics. Hospitals and endoscopy centres hold the largest revenue share, processing the highest flexible endoscopy procedure volume across the broadest scope model mix of any setting. Ambulatory surgical centres are expected to register a rapid revenue growth rate in the global flexible endoscopes market over the forecast period, driven by colonoscopy and upper GI endoscopy migration to ASC settings and the resulting flexible scope capital procurement need as ASC programmes acquire dedicated gastroscope and colonoscope inventory to replace hospital outpatient endoscopy referral dependencies.

Based on regional analysis, the flexible endoscopes market in Asia Pacific accounted for largest revenue share in 2025 at approximately 32%, anchored by Olympus's Tokyo headquarters domestic market strength, Japan's world-leading per-capita flexible endoscopy procedure rate, and China's large hospital endoscopy department installed base. Olympus holds approximately 70% of the global flexible GI endoscope market, with Asia Pacific representing the largest geographic revenue contributor through Japan domestic market penetration and Korea, Australia, and Southeast Asia installed base expansion. China hospital procurement centralisation constrains Olympus China ASP, but volume growth from new hospital endoscopy programme capacity expansion sustains the Asia Pacific revenue leadership position. The flexible endoscope supply chains at Olympus, FUJIFILM, and Hoya Pentax Medical are concentrated in Japanese manufacturing facilities outside the Strait of Hormuz logistics corridors, so Iran-US sanctions disruption does not materially affect flexible endoscope component availability or pricing at Japan-headquartered endoscope manufacturers.

The market in North America is expected to register the fastest revenue growth rate over the forecast period. The United States drives North American growth through Olympus Q2 FY2025 44% GI system sales growth as EVIS X1 adoption accelerates at hospital endoscopy departments that deferred capital replacement during the post-pandemic capital constraint period, combined with ASC colonoscopy and upper GI endoscopy migration generating new flexible scope capital procurement at commissioning ASC programmes. The North America flexible endoscopy capital replacement cycle is the primary near-term driver of Olympus ESD revenue growth through the 2026 to 2028 period.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national flexible endoscope markets within Europe. NHS England's GBP 4.1 billion endoscopy infrastructure programme is driving colonoscope and gastroscope capital procurement at NHS trust endoscopy units expanding diagnostic capacity. FUJIFILM ELUXEO 7000 series has achieved meaningful academic medical centre penetration in Germany and France as an alternative to Olympus EVIS X1 in the premium GI endoscope category.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national flexible endoscope markets. Brazil's private hospital and endoscopy clinic network in major urban centres is the primary flexible scope capital procurement setting, with Olympus and FUJIFILM the primary vendors at Brazilian endoscopy centre accounts.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and UAE represent the primary GCC markets. Saudi Vision 2030 hospital infrastructure expansion is driving endoscopy suite fit-out procurement at new tertiary hospital facilities, with Olympus the primary flexible endoscope vendor at GCC hospital endoscopy department capital procurement decisions.